Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT04514003
Active, not recruiting Observational

The Corona and COVID-19 Study in Telemark and Agder

NCT04514003 · tracked via the Priya Life Science Norway tracker
Sponsor
Sykehuset Telemark
Phase
Observational
Started
2020-07-01
Last updated
2024-11-29

Condition(s) studied

Covid19

Study summary

Through SARS-CoV-2 IgG testing of PCR positive and negative cases the study will follow the COVID-19 immune response by monitoring the SARS-CoV-2 IgG antibody levels over a period of two years. Further, risk factors will be identified by the use of the test-negative design including population controls, allowing comparison of participants with positive and negative tests, and with population controls (triangulation). Special emphasis will be on high risk groups in general and on different occupational, environmental and socio-economic groups in particular. Finally, severity of illness, deaths and the use of health care during will be assessed using national register data from Telemark and Agder.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age 18 - 85 years * Performed SARS-CoV-2 PCR test Exclusion Criteria: * Non-Norwegian speakers. * Deceased * inability to answer questionnaire due to dementia or similar conditions

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Telemark Hospital Skien Vestfold and Telemark

More Sykehuset Telemark trials in Norway

Breast Aesthetics by Three Dimensional Measures Active, not recruiting
Improved Selection of Elderly (> 65 Years) for Kidney Transplantation Active, not recruiting
Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors Recruiting
A Population-based Investigation of Asthma in the Telemark Region of Norway Active, not recruiting
The NOrwegian Tick-borne Encephalitis Study Active, not recruiting

Other trials for the same condition

Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04514003 on ClinicalTrials.gov ↗ ← All trials in Norway